Compare ACADIA Pharmaceuticals Inc. (ACAD) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs T-Mobile Us Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while T-Mobile Us Inc trades at $180.31 (market cap $199.92B). The key difference: T-Mobile Us Inc is far larger — about 44.5× ACADIA Pharmaceuticals Inc.'s market cap, and T-Mobile Us Inc pays a 2.21% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | TMUS | |
|---|---|---|
Market Cap | $4.49B | $199.92B |
Sector | Health | Media |
52-Week High | $28.06 | $259.01 |
52-Week Low | $20.06 | $167.65 |
Enterprise Value | $3.69B | $317.61B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
T-Mobile US (TMUS) trades at $184.73, up 4.06% on the day, with a bullish analyst consensus but bearish technical signals. The stock shows strong fundamentals with revenue growth to $88.31B in 2025 and a net income margin of 11.65%, though earnings have been mixed with a recent miss in Q4 2025. Recent news includes leadership changes and speculation about SpaceX's potential interest, while cash flow remains positive but projected to decline in 2026.
Outlook: TMUS offers growth potential with solid profitability and analyst targets near $256, but faces risks from competitive pressures and debt levels. Investment appeal hinges on execution amid sector volatility and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
